Apatinib attenuates phenotypic switching of arterial smooth muscle cells in vascular remodelling by targeting the PDGF Receptor‐β

Apatinib (YN968D1) is a small‐molecule tyrosine kinase inhibitor（TKI）which can inhibit the activity of vascular endothelial growth factor receptor‐2 (VEGFR‐2). It has been reported that apatinib has anti‐tumour effect of inhibiting proliferation and inducing apoptosis of a variety of solid tumour ce...

Descripción completa

Detalles Bibliográficos
Autores principales: Shao, Wenchao, Li, Xiaoguang, Peng, Jiangtong, Fan, Siyuan, Liang, Minglu, Huang, Kai
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7520274/
https://www.ncbi.nlm.nih.gov/pubmed/32697395
http://dx.doi.org/10.1111/jcmm.15623

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7520274/
https://www.ncbi.nlm.nih.gov/pubmed/32697395
http://dx.doi.org/10.1111/jcmm.15623

Ejemplares similares